Roche touts ‘best-in-disease’ potential for anti-hypertensive zilebesiran
While AstraZeneca’s first-in-class candidate baxdrostat marks phase III hypertension win…
While AstraZeneca’s first-in-class candidate baxdrostat marks phase III hypertension win at ESC 2025.